Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 3
Submit an article Journal homepage
3,869
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Harmonizing PD-L1 testing in metastatic triple negative breast cancer

Federica Giuglianoa European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy
,
Gabriele Antonarellia European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy
,
Paolo Tarantinoa European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy
,
Javier Cortesc International Breast Cancer Center (IBCC), Quironsalud Group, Madrid & Barcelona, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
,
Hope S. Rugod University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
&
Giuseppe Curiglianoa European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hematology (DIPO), University of Milan, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1781-2518
ORCID Icon
Pages 345-348 | Received 22 Oct 2021, Accepted 17 Dec 2021, Published online: 29 Dec 2021

References

  • Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121 .
  • Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–993.
  • Cortes J KEYNOTE-355: final results from a randomized, double-blind phase 3 study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. ESMO Congress 2021 LBA16. 2021 .
  • Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–1828.
  • Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–362.
  • Rozenblit M, Huang R, Danziger N, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020;8:e001558.
  • Scott M, Scorer P, Barker C, et al. Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol. 2019;30:iii4.
  • Rugo HS, Loi S, Adams S, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab -paclitaxel–treated advanced triple-negative breast cancer. JNCI J Natl Cancer Inst. 2021;113(12):1733–1743 .
  • Sanchez K, Kim I, Chun B, et al. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. Breast Cancer Res. 2021;23:2.
  • Liu J, Zheng Q, Mu X, et al. Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma. Sci Rep. 2021;11:15907.
  • Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019;30:1653–1659.
  • Blank CU, Haanen JB, Ribas A, et al. The “cancer immunogram”. Science. 2016;352:658–660.
  • Tarantino P, Curigliano G. Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opin Biol Ther. 2019;19:383–385.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.